TARGET and expanded access trials.

Abbreviations: AE = adverse event; CI = confidence interval; CR = complete response; ECOG PS = Eastern Cooperative Oncology Group performance status; HFSR = hand-foot skin reaction; HR = hazard ratio; MSKCC = Memorial Sloan Kettering Cancer Center; NE = estimable; NR = not reported; OS = overall survival; PBO = placebo; PFS = progression-free survival; PR = partial response; SAE = serious adverse event; SD = stable disease.a Unless otherwise specified, refers to entire study population.b Data missing for 36 pts.c Data missing for 2 pts.d Data missing for 5 pts.e Eligibility criteria included ECOG PS 0–2 with waivers granted to selected pts with PS 3 or 4.f n = 1891.g Considered treatment related.h All reported AEs were considered treatment related.TARGET and expanded access trials.缩写说明：AE=不良事件（adverse event）；CI=置信区间（confidence interval）；CR=完全缓解（complete response）；ECOG PS=东部肿瘤协作组体能状态评分（Eastern Cooperative Oncology Group performance status）；HFSR=手足皮肤反应（hand-foot skin reaction）；HR=风险比（hazard ratio）；MSKCC=纪念斯隆凯特琳癌症中心（Memorial Sloan Kettering Cancer Center）；NE=可评估（estimable）；NR=未报告（not reported）；OS=总生存期（overall survival）；PBO=安慰剂（placebo）；PFS=无进展生存期（progression-free survival）；PR=部分缓解（partial response）；SAE=严重不良事件（serious adverse event）；SD=疾病稳定（stable disease）。 a 除非另有说明，均指代整个研究人群。 b 36例患者数据缺失。 c 2例患者数据缺失。 d 5例患者数据缺失。 e 入组标准为东部肿瘤协作组体能状态评分0~2分，部分体能状态评分为3或4分的患者可获批豁免该标准。 f 样本量n=1891。 g 该事件被认定与治疗相关。 h 所有报告的不良事件均被视为与治疗相关。 本研究数据来自TARGET试验及扩展准入试验。